Why CRISPR Therapeutics' Stock Is Trading Higher Today

CRISPR Therapeutics AG CRSP shares are trading higher after the company reported Q2 earnings per share results of $9.44, up from $(1.30) year-over-year.

'We expect to report clinical data from our immuno-oncology programs later this year and to file multiple INDs for our regenerative medicine and in vivo programs in the next 18 to 24 months,' said Samarth Kulkarni, Ph.D., Chief Executive Officer of CRISPR Therapeutics.

CRISPR Therapeutics AG is a gene-editing company. It is engaged in the development of CRISPR/Cas9-based therapeutics.

CRISPR's stock was trading about 5.5% higher after hours at $125.50 per share on Thursday. The stock has a 52-week high of $220.20 and a 52-week low of $76.71.

Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Date
ticker
name
Actual EPS
EPS Surprise
Actual Rev
Rev Surprise
Posted In: EarningsNewsMoversTrading Ideaswhy it's moving
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!